Investor Relations

VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26

February 19, 2019

TEL AVIV, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announces that the Company will present new data on the potential of its VB-600 platform targeting MOSPD2 for inflammatory and oncology indications, at the Keystone Symposia on Myeloid Cells, to be held February 24—28, 2019 at the Eldorado Hotel & Spa in Santa Fe, New Mexico.

Oral Presentation Details:    
Title:    MOSPD2: Key Regulator of Myeloid Cell Migration and a Novel Target for Treatment of Inflammatory Diseases 
Presenter:   Itzhak Mendel, PhD
Date:   Tuesday, February 26, 2019
Time:    8:00 – 11:00 AM MST
Session:    Myeloid Cells in Metabolic and Inflammatory Diseases
Location:   Eldorado Grand Ballroom
Poster Presentation Details:    
Abstract:    MOSPD2: Key Regulator of Myeloid Cell Migration and a Novel Target for Treatment of Inflammatory Diseases
Session title:    Poster Session 2
Date:    Tuesday, February 26, 2019
Time:    7:30 - 10:00 PM MST
Poster #:   2028

For more information on the Keystone Symposium on Myeloid Cells, including a detailed program, refer to

About VBL's VB-600 Platform

VBL is conducting two parallel drug development programs that are exploring the potential of MOSPD2, a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer. Our VB-600 platform comprises classical anti-MOSPD2 monoclonal antibodies for inflammatory indications, as well as bi-specific antibody candidates for oncology.

About VBL

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a potential registration trial for platinum-resistant ovarian cancer.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding our programs, including VB-111, including their clinical development, such as the timing thereof, therapeutic potential and clinical results, and the scope and protection of our intellectual property rights. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, and that we may not realize the expected benefits of our intellectual property protection. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2017, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Michael Rice
LifeSci Advisors, LLC
(646) 597-6979

VBL Logo.jpg